A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial† (Englisch)
- Neue Suche nach: Fuchs, C. S.
- Neue Suche nach: Azevedo, S.
- Neue Suche nach: Okusaka, T.
- Neue Suche nach: Van Laethem, J. L.
- Neue Suche nach: Lipton, L. R.
- Neue Suche nach: Riess, H.
- Neue Suche nach: Szczylik, C.
- Neue Suche nach: Moore, M. J.
- Neue Suche nach: Peeters, M.
- Neue Suche nach: Bodoky, G.
- Neue Suche nach: Fuchs, C. S.
- Neue Suche nach: Azevedo, S.
- Neue Suche nach: Okusaka, T.
- Neue Suche nach: Van Laethem, J. L.
- Neue Suche nach: Lipton, L. R.
- Neue Suche nach: Riess, H.
- Neue Suche nach: Szczylik, C.
- Neue Suche nach: Moore, M. J.
- Neue Suche nach: Peeters, M.
- Neue Suche nach: Bodoky, G.
In:
ANNALS OF ONCOLOGY
;
26
, 5
;
921-927
;
2015
-
ISSN:
- Aufsatz (Zeitschrift) / Print
-
Titel:A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial†
-
Beteiligte:Fuchs, C. S. ( Autor:in ) / Azevedo, S. ( Autor:in ) / Okusaka, T. ( Autor:in ) / Van Laethem, J. L. ( Autor:in ) / Lipton, L. R. ( Autor:in ) / Riess, H. ( Autor:in ) / Szczylik, C. ( Autor:in ) / Moore, M. J. ( Autor:in ) / Peeters, M. ( Autor:in ) / Bodoky, G. ( Autor:in )
-
Erschienen in:ANNALS OF ONCOLOGY ; 26, 5 ; 921-927
-
Verlag:
- Neue Suche nach: OXFORD UNIVERSITY PRESS
-
Erscheinungsdatum:01.01.2015
-
Format / Umfang:7 pages
-
ISSN:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Print
-
Sprache:Englisch
- Neue Suche nach: 616.992
- Weitere Informationen zu Dewey Decimal Classification
-
Klassifikation:
DDC: 616.992 -
Datenquelle:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Inhaltsverzeichnis – Band 26, Ausgabe 5
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 827
-
Adapting the drivers to the road: a new strategy for cancer evolution?Touat, M. / Dhermain, F. / André, F. / Sanson, M. et al. | 2015
- 829
-
An ESMO-EORTC position paper on the EU clinical trials regulation and EMA's transparency policy: making European research more competitive againDittrich, C. / Negrouk, A. / Casali, P. G. et al. | 2015
- 833
-
Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancerOldenburg, J. / Aparicio, J. / Beyer, J. / Cohn-Cedermark, G. / Cullen, M. / Gilligan, T. / De Giorgi, U. / De Santis, M. / de Wit, R. / Fosså, S. D. et al. | 2015
- 838
-
Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumorsSerpico, D. / Trama, A. / Haspinger, E. R. / Agustoni, F. / Botta, L. / Berardi, R. / Palmieri, G. / Zucali, P. / Gallucci, R. / Broggini, M. et al. | 2015
- 848
-
Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysisLouie, K. S. / Seigneurin, A. / Cathcart, P. / Sasieni, P. et al. | 2015
- 865
-
Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†Bellera, C. A. / Penel, N. / Ouali, M. / Bonvalot, S. / Casali, P. G. / Nielsen, O. S. / Delannes, M. / Litière, S. / Bonnetain, F. / Dabakuyo, T. S. et al. | 2015
- 873
-
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†Gourgou-Bourgade, S. / Cameron, D. / Poortmans, P. / Asselain, B. / Azria, D. / Cardoso, F. / A'Hern, R. / Bliss, J. / Bogaerts, J. / Bonnefoi, H. et al. | 2015
- 880
-
Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosomeFavero, F. / McGranahan, N. / Salm, M. / Birkbak, N. J. / Sanborn, J. Z. / Benz, S. C. / Becq, J. / Peden, J. F. / Kingsbury, Z. / Grocok, R. J. et al. | 2015
- 888
-
Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902Sugawara, S. / Oizumi, S. / Minato, K. / Harada, T. / Inoue, A. / Fujita, Y. / Maemondo, M. / Yoshizawa, H. / Ito, K. / Gemma, A. et al. | 2015
- 894
-
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†Blumenschein, G. R. / Smit, E. F. / Planchard, D. / Kim, D. W. / Cadranel, J. / De Pas, T. / Dunphy, F. / Udud, K. / Ahn, M. J. / Hanna, N. H. et al. | 2015
- 902
-
Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosisJanssen-Heijnen, M. L. / van Erning, F. N. / De Ruysscher, D. K. / Coebergh, J. W. / Groen, H. J. et al. | 2015
- 908
-
Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†Pujol, J. L. / Lavole, A. / Quoix, E. / Molinier, O. / Souquet, P. J. / Barlesi, F. / Le Caer, H. / Moro-Sibilot, D. / Fournel, P. / Oster, J. P. et al. | 2015
- 914
-
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study†Monk, B. J. / Ghatage, P. / Parekh, T. / Henitz, E. / Knoblauch, R. / Matos-Pita, A. S. / Nieto, A. / Park, Y. C. / Cheng, P. S. / Li, W. et al. | 2015
- 921
-
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial†Fuchs, C. S. / Azevedo, S. / Okusaka, T. / Van Laethem, J. L. / Lipton, L. R. / Riess, H. / Szczylik, C. / Moore, M. J. / Peeters, M. / Bodoky, G. et al. | 2015
- 928
-
Nomograms to predict survival and the risk for developing local or distant recurrence in patients with rectal cancer treated with optional short-term radiotherapyvan Gijn, W. / van Stiphout, R. G. / van de Velde, C. J. / Valentini, V. / Lammering, G. / Gambacorta, M. A. / Påhlman, L. / Bujko, K. / Lambin, P. et al. | 2015
- 935
-
The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYCTakahashi, Y. / Sheridan, P. / Niida, A. / Sawada, G. / Uchi, R. / Mizuno, H. / Kurashige, J. / Sugimachi, K. / Sasaki, S. / Shimada, Y. et al. | 2015
- 943
-
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancerChen, J. S. / Hsu, C. / Chiang, N. J. / Tsai, C. S. / Tsou, H. H. / Huang, S. F. / Bai, L. Y. / Chang, I. C. / Shiah, H. S. / Ho, C. L. et al. | 2015
- 950
-
Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†Renfro, L. A. / Grothey, A. / Kerr, D. / Haller, D. G. / André, T. / Van Cutsem, E. / Saltz, L. / Labianca, R. / Loprinzi, C. L. / Alberts, S. R. et al. | 2015
- 958
-
Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphomaBarta, S. K. / Samuel, M. S. / Xue, X. / Wang, D. / Lee, J. Y. / Mounier, N. / Ribera, J. M. / Spina, M. / Tirelli, U. / Weiss, R. et al. | 2015
- 966
-
Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL)Chihara, D. / Asano, N. / Ohmachi, K. / Nishikori, M. / Okamoto, M. / Sawa, M. / Sakai, R. / Okoshi, Y. / Tsukamoto, N. / Yakushijin, Y. et al. | 2015
- 973
-
A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas—NCIC-CTG IND 200†Chu, Q. S. / Nielsen, T. O. / Alcindor, T. / Gupta, A. / Endo, M. / Goytain, A. / Xu, H. / Verma, S. / Tozer, R. / Knowling, M. et al. | 2015
- 981
-
Non-intercepted dose errors in prescribing anti-neoplastic treatment: a prospective, comparative cohort studyMattsson, T. O. / Holm, B. / Michelsen, H. / Knudsen, J. L. / Brixen, K. / Herrstedt, J. et al. | 2015
- 987
-
Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastasesde Baère, T. / Aupérin, A. / Deschamps, F. / Chevallier, P. / Gaubert, Y. / Boige, V. / Fonck, M. / Escudier, B. / Palussiére, J. et al. | 2015
- 992
-
Drug–drug interactions in patients treated for cancer: a prospective study on clinical interventions†van Leeuwen, R. W. / Jansman, F. G. / van den Bemt, P. M. / de Man, F. / Piran, F. / Vincenten, I. / Jager, A. / Rijneveld, A. W. / Brugma, J. D. / Mathijssen, R. H. et al. | 2015
- 998
-
Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignanciesWong, A. L. / Soo, R. A. / Tan, D. S. / Lee, S. C. / Lim, J. S. / Marban, P. C. / Kong, L. R. / Lee, Y. J. / Wang, L. Z. / Thuya, W. L. et al. | 2015
- 1005
-
Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer—results of a first-in-man dose-escalation study with a fixed-dose extension phaseIsambert, N. / Delord, J. P. / Soria, J. C. / Hollebecque, A. / Gomez-Roca, C. / Purcea, D. / Rouits, E. / Belli, R. / Fumoleau, P. et al. | 2015
- 1012
-
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradationFu, S. / Hou, M. M. / Naing, A. / Janku, F. / Hess, K. / Zinner, R. / Subbiah, V. / Hong, D. / Wheler, J. / Piha-Paul, S. et al. | 2015
- 1019
-
Molecular phenotypes of DCIS predict overall and invasive recurrence†Williams, K. E. / Barnes, N. L. / Cramer, A. / Johnson, R. / Cheema, K. / Morris, J. / Howe, M. / Bundred, N. J. et al. | 2015
- 1025
-
Long-term effects of inhaled budesonide on screening-detected lung nodulesVeronesi, G. / Lazzeroni, M. / Szabo, E. / Brown, P. H. / DeCensi, A. / Guerrieri-Gonzaga, A. / Bellomi, M. / Radice, D. / Grimaldi, M. C. / Spaggiari, L. et al. | 2015
- 1031
-
Reply to the letter to the editor ‘Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis’ by Louie et al.Louie, K. S. / Seigneurin, A. / Cathcart, P. / Sasieni, P. et al. | 2015
- 1031
-
Letter to the editor concerning ‘Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis’Carlsson, S. / Assel, M. / Vickers, A. et al. | 2015
- 1032
-
Choosing a better end point for trials of bone-protective agentsLeibowitz-Amit, R. / Khoja, L. / Tannock, I. F. / Joshua, A. M. et al. | 2015
- 1033
-
Letter to the editor concerning ‘Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA’Foglietta, J. / Metro, G. / Crinò, L. / Gori, S. et al. | 2015
- 1034
-
How can I validate a nomogram? Show me the modelCollins, G. S. et al. | 2015
- 1035
-
Concomitant EGFR and KRAS mutations in ALK-rearranged lung cancerRossi, G. / Baldi, L. / Barbieri, F. / Bertolini, F. / Tiseo, M. et al. | 2015
- 1036
-
Recent developments in the implementation of novel designs for early-phase combination studiesWages, N. A. / Conaway, M. R. / Slingluff, C. L. / Williams, M. E. / Portell, C. A. / Hwu, P. / Petroni, G. R. et al. | 2015
- 1038
-
A 3′-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma| 2015
- 1040
-
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trialHebbar, M. / Chibaudel, B. / André, T. / Mineur, L. / Smith, D. / Louvet, C. / Dutel, J. L. / Ychou, M. / Legoux, J. L. / Mabro, M. et al. | 2015